Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Common Equity (2016 - 2025)

Lisata Therapeutics (LSTA) has disclosed Common Equity for 12 consecutive years, with $20.8 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Common Equity fell 45.32% year-over-year to $20.8 million, compared with a TTM value of $20.8 million through Jun 2025, down 45.32%, and an annual FY2024 reading of $29.3 million, down 38.79% over the prior year.
  • Common Equity was $20.8 million for Q2 2025 at Lisata Therapeutics, down from $25.1 million in the prior quarter.
  • Across five years, Common Equity topped out at $60.7 million in Q1 2023 and bottomed at $20.8 million in Q2 2025.
  • Average Common Equity over 3 years is $40.8 million, with a median of $40.4 million recorded in 2024.
  • The sharpest move saw Common Equity decreased 29.59% in 2024, then plummeted 45.32% in 2025.
  • Year by year, Common Equity stood at $47.9 million in 2023, then tumbled by 38.79% to $29.3 million in 2024, then dropped by 29.14% to $20.8 million in 2025.
  • Business Quant data shows Common Equity for LSTA at $20.8 million in Q2 2025, $25.1 million in Q1 2025, and $29.3 million in Q4 2024.